Bevacizumab biosimilar (Centus Biotherapeutics)

贝伐珠单抗生物类似药 (Centus Biotherapeutics)

Report date: 2024/02/26 16:43:35

Base Information

Drug NameBevacizumab biosimilar (Centus Biotherapeutics)
Drug Alias Name贝伐单抗生物仿制药 (Centus Biotherapeutics)贝伐人源化单抗生物仿制药 (Centus Biotherapeutics)贝伐赛珠单抗生物仿制药 (Centus Biotherapeutics)贝伐珠单抗生物仿制药 (Centus Biotherapeutics)Equidacent +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2020/09/24
Country/TerritoryBosnia and HerzegovinaBulgariaUnited States +[25] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesFujifilm Kyowa Kirin Biologics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCentus Biotherapeutics Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsColorectal Neoplasms +[7] 

Other Information

ATC CodeL01XC07
Related LinksWikipediaDrugBankKEGG